Clarifying oligometastatic non-small cell lung cancer in patients with local ablative therapies for oligoprogression after tyrosine kinase inhibitors
D. Hyun (Seoul, Republic of Korea), Y. Jang (Seoul, Republic of Korea), W. Ji (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), D. Lee (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), S. Yoon (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea)
Source: International Congress 2022 – Diagnostics and biomarkers in lung cancer
Session: Diagnostics and biomarkers in lung cancer
Session type: Thematic Poster
Number: 1142
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Hyun (Seoul, Republic of Korea), Y. Jang (Seoul, Republic of Korea), W. Ji (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), D. Lee (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), S. Yoon (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea). Clarifying oligometastatic non-small cell lung cancer in patients with local ablative therapies for oligoprogression after tyrosine kinase inhibitors. 1142
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|